Summary of Neos Therapeutics, Inc. (NASDAQ:NEOS) Ratings

April 20, 2018 - By Arturo Altman

Neos Therapeutics, Inc. (NASDAQ:NEOS) Corporate Logo

Neos Therapeutics, Inc. (NASDAQ:NEOS) Ratings Coverage

A total of 3 analysts rate Neos Therapeutics (NASDAQ:NEOS) as follows: 2 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 67% are bullish. (NASDAQ:NEOS) has 5 ratings reports on Apr 20, 2018 according to StockzIntelligence. On Thursday, October 26 BMO Capital Markets maintained Neos Therapeutics, Inc. (NASDAQ:NEOS) rating. BMO Capital Markets has “Buy” rating and $14.0 target. On Wednesday, January 31 the stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) earned “Market Perform” rating by BMO Capital Markets. On Thursday, March 15 the rating was maintained by Cantor Fitzgerald with “Buy”. On Wednesday, November 8 the firm earned “Buy” rating by Cantor Fitzgerald. Listed here are Neos Therapeutics, Inc. (NASDAQ:NEOS) PTs and latest ratings.

15/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0 Maintain
31/01/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Downgrade
08/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0 Maintain
26/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $14.0 Maintain
26/10/2017 Broker: Cowen & Co Rating: Buy

NEOS touched $8.15 during the last trading session after $0.05 change.Neos Therapeutics, Inc. has volume of 12,573 shares. Since April 20, 2017 NEOS has risen 12.33% and is uptrending. NEOS outperformed the S&P 500 by 0.78%.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.The firm is worth $236.33 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.Last it reported negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

Neos Therapeutics, Inc. (NASDAQ:NEOS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.